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Summary Changes in the expression of Lewis antigens have been associated with cancer diseases, and recent
results have pointed at a possible increased risk of cancer development among Lewis negative patients. The
frequency of the erythrocyte Lewis phenotypes Le'-b +, Lea+b- and Lea-b- was analysed in patients suffering
from urinary bladder cancer (82), colon cancer (21), and benign urological diseases (45). An increased
frequency of Lewis negative individuals was found among colon cancer patients (P<0.004) and bladder
cancer patients (P = 0.05). The Lewis negative phenotype was shown to be associated with unfavourable
disease parameters: invasion (P <0.02) and high grade of atypia (P <0.01) in bladder cancer patients, and
high Dukes stage (P <0.05) in colon cancer patients. al-4fucosyltransferase activity (Lewis transferase) was
shown to be present in saliva from four out ofeight erythrocyte Lewis negative cancer patients, indicating that
some patients with advanced cancer disease may have converted from a Lewis positive to a Lewis negative
phenotype.
The association between various diseases and the existence or
neosynthesis of certain carbohydrate antigen structures has
been given special attention in recent years. Several of these
carbohydrate structures are blood group antigens, among
which particular interest has been given to the Lewis antigen
system.
Compared to other erythrocyte blood-group systems the
Lewis blood group system is unique as the Lewis active
glycolipids are not synthesised in the erythrocytes but
acquired from plasma (Sneath & Sneath, 1959; Marr et al.,
1967; Marcus & Cass, 1969). The Lea antigen determinant
(GalPl-3[Fucxl-4]GlcNAc-R) is synthesised by the action of
an al-4-L-fucosyltransferase encoded by the Lewis gene
(Shen, Grollman & Ginsburg, 1968), and the activity of this
enzyme can be determined in saliva. The Leb antigen deter-
minant (Fuccxl-2Galp1-3[Fucocl-4]GlcNAc-R) is formed by
the sequential action of an al-2-L-fucosyltransferase and the
a1-4-L-fucosyltransferase (Grollman, Kobata & Ginsburg,
1989).
Several investigations have described an incompatibility of
Lewis erythrocyte phenotype and saliva or serum Lewis
antigens associated with different pathologic conditions. One
study showed the prevalence of erythrocyte Laa-b-
phenotype to be significantly higher in patients with pan-
creatic cancer than normal controls (Hirano et al., 1987).
Another study has shown that 11 out of 18 patients studied,
predominantly with gastrointestinal cancers, had inappro-
priate Lewis blood group antigens in their erythrocytes and
saliva, with an increased frequency of the Lea -b - phenotype
among these patients (Yazawa et al., 1988). In addition,
pregnant women and patients with alcoholic cirrhosis and
alcoholic pancreatitis seem to lose their Lewis phenotype on
erythrocytes (Hammar et al., 1981; Stigendal et al., 1984).
These findings seem to point at a possible dissociation
between the Lewis phenotype of erythrocytes, and genotype
in the same individual.
The intention of the present paper was to analyse and
compare the distribution of the Lewis erythrocyte phenotype
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in patients suffering from carcinoma ofthe bladder and colon
to the distribution found in normal controls, and to correlate
the different phenotypes to biological parameters like stage,
pathologic grade and invasion.
Materials and methods
Patients andsamples
Ten ml samples of human whole blood were obtained from
82 patients suffering from urinary bladder carcinomas, 21
patients suffering from carcinoma of the colon (Table III), 26
patients suffering from hyperplasia of the prostate, and from
19 patients suffering from chronic cystitis (Table IV). The
samples were used for serology within 24 h. Saliva samples
were obtained simultaneously with the blood samples from
some of the patients. One ml saliva was stored at - 80°C for
enzyme analysis and I ml was stored at - 20°C for hemag-
glutination inhibition tests.
Pathology
Data on the grade of atypia (Bergkvist et al., 1965) presence
or absence of invasion and Dukes stage were obtained from
routine pathologic examination. The diagnosis chronic cys-
titis was based on histopathologic examination of bladder
mucosa biopsies.
Controls
398 ABO and Lewis phenotypes consecutively collected
volunteer blood donors from the Department of Clinical
Immunology, Skejby Hospital, served as controls in this
study. They were all recruited from the same population and
typed by the same methods in the same laboratory, as were
the cancer patients.
Serology
All erythrocytes were subjected to routine blood bank pro-
cedures, whereby the ABO and Lewis phenotypes were deter-
mined by hemagglutination test. The reagents used were
polyclonal human and goat antisera (Ortho Diagnostic
Systems, Rariton, NJ, USA) and Dolichos Biflorus and Ulex
Europaeus agglutinins (Sigma Chemical Co., St. Louis, Mo.,
USA). ABH and Lewis antigens in saliva were detected with
identical sera and lectins by low ion strength hemagglutina-
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tion inhibition tests. In all assays appropriate known controls
were included.
Fucosyltransferase assay
The method has been described in details by 0rntoft et al.
(1988). In short, the saliva samples were centrifuged and the
supernatants added to GDP-L-['4C]fucose, ATP, and the
acceptor lacto-N-biose I. The incubation mixtures were then
chromatographed on Whatman No. 40 paper in solvent for
48 h, and the paper was scanned for radioactivity in a
Packard radiochromatogram scanner. The mobilities of the
radioactive compounds were cut out and counted by liquid
scintillation spectrometry.
Statistics
To test the distribution of Lewis phenotypes among cancer
patients against the control group a stratified Chi-square test
was used. Lea b+ and Lea
+ b-individuals were grouped as
one Lewis positive group. Due to the inequality in the
relative contribution to Lewis phenotypes from each single
ABO phenotype, a stratification according to ABO blood
group was used (see footnote to Table I). Fisher's exact test
was used to test the relation between Dukes stage, grade of
atypia and invasion to the distributions of Lewis phenotypes.
Results
The distribution of ABO and Lewis phenotypes among colon
and bladder cancer patients is shown in Table I. No statis-
tically significant differences in the distribution of ABO
phenotypes were found between cancer patients and the
volunteer donor population, whereas the incidence of Lea b-
phenotype among colon cancer (23.8%) and bladder cancer
patients (12.2%) was significantly higher when compared to
the volunteer donor population (7.1%) (P <0.003 and
P = 0.05, respectively) (Table I). The distribution of ABO
and Lewis phenotypes among patients suffering from the
benign diseases hypertrophia of the prostate and chronic
cystitis (Table II) was not significantly different from the
distribution found in the volunteer donor population.
Table III shows the distribution of Lewis phenotypes
among the group of colon cancer patients in relation to
Dukes classification of tumours. Dukes stage C was the most
common stage in Lea-b- individuals, and this proved to be
statistically significant at the P <0.05 level.
The relation between Lewis phenotype, grade of atypia,
and the presence or absence of invasion in bladder tumours
is shown in Table IV. Compared to patients with the Lewis
positive phenotypes (Lea +b- and Lea-Ib,), it turned out that
a statistically higher number of Lewis negative patients had
grade III and IV tumours (P <0.01). In addition, these nine
Lewis negative patients had invasive tumours. Compared to
patients with Lewis positive phenotypes, this was significant
at the P <0.02 level.
Table V shows the results of Lewis transferase (al-4-
fucosyltransferase) assays and secretor status in eight eryth-
rocyte Lewis negative patients, five suffering from invasive
grade III or IV bladder carcinomas and three suffering from
Dukes stage C colon carcinomas. Four of these eight
patients, all secretors, had ax-1-4-fucosyltransferase activity in
saliva. These four patients were considered non-genuine
Lewis negative. The other four patients were considered
genuine Lewis negative.
Discussion
This study shows an increased frequency of the erythrocyte
Lea b-phenotype among patients with colon and bladder
cancer. The increased frequency of Lea-b- erythrocyte
phenotype was not present when patients suffering from the
benign diseases chronic cystitis and hypertrophia of the pros-
tate were examined. In addition, the Lea b-phenotype was
shown to be associated with unfavourable disease parameters
like invasion and high grade of atypia in bladder cancer
patients, and high Dukes stage in colon cancer patients.
The increased frequency of the erythrocyte Lea b-
phenotype among the cancer patients could be due to an
increased risk of cancer among these individuals, or due to
the loss of detectable Lewis antigens on their erythrocytes.
We therefore tested the activity of the Lewis transferase in
saliva from patients where saliva was obtainable. The tests
showed activity of the Lewis transferase in saliva from four
out of eight cancer patients, classified as Lea b- on the basis
of their erythrocytes. These results strongly support the belief
that some cancer patients with advanced disease convert
from a Lewis positive to a Lewis negative phenotype, and
Table I Distribution of the ABO and Lewis blood-group phenotypes among 82 patients suffering
from urinary bladder tumours and 21 patients suffering from colon carcinomas
Colon tumours Bladder tumours Controlsa
Female Male Total Female Male Total Total
N:12 N:9 N:21 N:28 N:54 N:82 N:398
A 7 4 11 (52.4)b 9 24 33 (40.2) 174 (43.7)
B 0 1 1 (4.8) 2 6 8 (9.8) 44 (11.1)
AB 0 0 0 (0.0) 1 6 7 (8.5) 16 (4.0)
0 5 4 9 (42.9) 16 18 34 (41.5) 164 (41.2)
Le(a-b+) 9 3 12 (57.1) 19 33 52 (63.4) 295 (74.1)
Le(a+b-) 2 2 4 (19.0) 7 13 20 (24.4) 75 (18.8)
Le(a-b- )c 1 4 5 (23.8)d 4 6 10 (12.2)' 28 (7.1)
Median age 68 66 66 73 68 70
Range (34-84) (31-88) (31-88) (36-91) (38-87) (36-91)
aVolunteer blood donors recruited from the same population as the patients. These figures are
similar to those published by others: A: 42%; B: I I%; AB: 4%; 0: 43%; Le(a - b +): 72%;
Le(a + b -): 22%; Le(a - b -): 6%; (Race & Sanger, 1975; Mollison et al., 1987; Issitt, 1985).
bFigures in brackets indicate percentages. cDistribution of ABO phenotypes among the ten bladder
tumour Le'-b patients: 0:4; A,:4; A2:1; B:1. distribution of ABO phenotypes among the five colon
tumour Lea b - patients: 0:2; A,:2; B:1. dStratified Chi-square test: P<0.003 tested against the
controls (volunteer blood donor). 'Stratified Chi-square test: P = 0.05 tested against the controls
(volunteer blood donors). Due to biochemical configurational differences, the Lewis negative
phenotype is more difficult to assay in ABO blood-group Al individuals (Mollison, Engelfriet &
Contreras, 1987). We therefore used a stratification according to ABO blood-groups in the
Chi-square test. Subdivided on ABO blood-groups, the relative frequency of the Le(a - b -)
phenotypes was among controls: A = 9.8%; 0 = 4.3%; B = 6.8%; AB = 6.2%, among bladder
cancer patients: A = 15.5%; 0 = 11.8%; B = 12.5%; AB = 0%, and among colon cancer patients:
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Table II Distribution of the ABO and Lewis blood group phenotypes among
patients suffering from non-malignant urological diseases: 19 patients with chronic
cystitis and 26 patients with hypertrophia of the prostate
Hypertrophia
Chronic cystitis of the prostate Controlsa
Female Male Total Total Total
N:7 N:12 N:19 N:26 N:398
A 1 7 8 (420)b 14 (54.0) 174 (43.7)
B 1 1 2 (10.5) 3 (11.5) 44 (11.1)
AB 0 0 0 (0.0) 0 (0.0) 16 (4.0)
0 5 4 9 (47.5) 9 (34.5) 164 (41.2)
Le(a-b+) 4 10 14 (74.0) 19 (73.1) 295 (74.1)
Le(a+b-) 3 2 5 (26.0) 5 (19.2) 75 (18.8)
Le(a-b-) 0 0 0 (0.0) 2 (7.7) 28 (7.1)
Median age 62 70 68 72
Range (40-84) (42-81) (40-84) (52-83)
aVolunteer blood donors recruited from the same population as the patients.
bFigures in brackets indicate percentages.
offer an explanation of the observed over-representation of
erythrocyte Lewis negative individuals among patients with
colon and bladder cancer.
Sheinfeld et al. found an increased frequency of Lea -b -
and Lea+b-phenotypes among white women with recurrent
urinary tract infections (Sheinfeld et al., 1989). This result
seems at first view to conflict with the results presented here
(Table II), but is explained by the fact that two different
Table III Correlation between the distribution of Lewis blood
group phenotype and Dukes stage in 21 patients suffering from
colonic carcinomas
Dukes type
A B C D Total
Le(a - b +) 2 7 3 0 12
Le(a+b-) 1 2 1 0 4
Le(a-b-) 1 0 4a 0 5
4 10 7 0 21
aFishers exact tests: P <0.05.
Table IV Correlation between the distribution of Lewis
blood-group phenotypes and (1) grade ofatypia and (2) the presence
or absence of invasion in 82 patients suffering from bladder
tumours
Grade of atypia' Invasion
II III IV + -
Le(a - b +) 20 26 6 24 28
Le(a+b-) 7 7 6 12 8
Le(a-b-) 1 3 6b 9c 1
aAccording to Bergkvist (Bergkvist et al., 1965). No grade I
tumours were found. bFisher's exact test: P <0.01. CFisher's exact
test: P<0.02.
pathological conditions were studied. In our material the
diagnosis 'chronic cystitis' covered a nonbacterial inflam-
matory condition, based upon pathologic examination of
bladder mucosa biopsies, while the diagnosis 'urinary tract
infection' in Sheinfeld's group of patients was based on
clinical symptoms and bacteriologic examinations.
The mechanism for the inappropriate Lewis blood group
antigen expression in cancer has been proposed to occur as
the result of changes in the specificity of glycosyltransferases,
competition for substrates between enzymes, activation of
cancer-related antigens, and disturbances in the equilibrium
between plasmalipoprotein and red cell mass (Schoentag et
al., 1987; Itzkowitz et al., 1986; Yazawa et al., 1986; Ham-
mar et al., 1989). The finding of serum Lewis antigen levels
in non-genuine Lewis negative individuals identical to the
ones found in Lewis positive individuals (0rntoft et al.,
1989), enforces the idea that the process by which eryth-
rocytes take up Lewis active glycolipids might be disturbed.
Further studies are needed to reveal the mechanism of the
changing of Lewis phenotype on erythrocytes.
The findings described here along with similar previous
observations (Hirano et al., 1987; Yazawa et al., 1988)
indicate that alterations in the expression of Lewis antigens is
a cancer-associated phenomenon. We conclude that the fre-
quency of the erythrocyte Le'
b-phenotype is increased in
patients who suffer from colorectal and bladder carcinomas
-
especially so in high grade invasive cases. This is probably
not to be explained by an increased risk of bladder cancer
among erythrocyte Lea
b-individuals, but by the fact that
individuals who are normally erythrocyte Lewis positive
become erythrocyte Lewis negative when they get an invasive
cancer.
Table V al-4-fucosyltransferase activity in saliva, secretor status, and ABO
blood group phenotype in eight erythrocyte Lewis negative cancer
patients
Anatomical Saliva
location of a4FT activity Secretor ABO
Patient carcinoma pmolhr-'mg-' protein statusa blood-group
Pt 06/20 Bladderb 442 Se 0
Pt 122 Bladder 608 Se Al
BI Bladder 637 Se 0
Pt 92/100 Bladder 0 NS Al
B27 Bladder 0 Se A2
C28 Colonc 530 Se A1B
C22/Cl Colon 0 NDd Al
C36/C3 Colon 0 Se 0
aSe: secretor; NS: non-secretor. bAll bladder tumours were invasive grade
III or IV carcinomas. CAll colon tumours were Dukes stage C. dND: not
-determined.586 N.C. LANGKILDE et al.
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